AnaptysBio, Inc. (NASDAQ: ANAB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.08 | Insider Own | 39.49% | Shs Outstand | 29.61M | Perf Week | 6.09% |
| Market Cap | 1.68B | Forward P/E | 28.95 | EPS next Y | 1.96 | Insider Trans | -0.28% | Shs Float | 27.75M | Perf Month | -14.99% |
| Enterprise Value | 1.71B | PEG | 0.18 | EPS next Q | - | Inst Own | - | Short Float | 18.01% | Perf Quarter | -15.46% |
| Income | -27.66M | P/S | 7.21 | EPS this Y | -40.08% | Inst Trans | - | Short Ratio | 7.25 | Perf Half Y | 77.29% |
| Sales | 232.39M | P/B | 127.42 | EPS next Y | 229.27% | ROA | -8.13% | Short Interest | 5.00M | Perf YTD | 75.15% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 442.91% | 52W High | 71.30 -21.77% | Perf Year | 276.65% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | 14.06% | 52W Low | 11.24 396.14% | Perf 3Y | 318.40% |
| Dividend Est. | - | EV/EBITDA | 29.15 | Sales past 3/5Y | 186.43% 25.66% | Gross Margin | - | Volatility | 4.19% 6.56% | Perf 5Y | 269.52% |
| Dividend TTM | - | EV/Sales | 7.34 | EPS Y/Y TTM | 78.91% | Oper. Margin | 17.56% | ATR (14) | 3.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.58 | Sales Y/Y TTM | 154.95% | Profit Margin | -11.53% | RSI (14) | 50.58 | Recom | 2.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.58 | EPS Q/Q | -43.75% | SMA20 | 2.24% | Beta | 0.82 | Target Price | 73.67 |
| Payout | 0.00% | Debt/Eq | 21.76 | Sales Q/Q | -7.14% | SMA50 | -1.23% | Rel Volume | 0.84 | Prev Close | 56.61 |
| Employees | 104 | LT Debt/Eq | 0.32 | Earnings | Aug 10 | SMA200 | 31.49% | Avg Volume | 641.25K | Price | 55.77 |
| IPO Date | Jan 26, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -185.91% 35.48% | Net Debt/EBITDA | 0.49 | Volume | 537,044 | Change | -1.48% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-15-26 | Reiterated | Leerink Partners | Outperform | $85 → $90 |
| May-13-26 | Reiterated | Barclays | Overweight | $55 → $75 |
| May-13-26 | Reiterated | UBS | Buy | $60 → $76 |
| Apr-28-26 | Reiterated | Leerink Partners | Outperform | $45 → $85 |
| Apr-21-26 | Reiterated | UBS | Buy | $70 → $60 |
| Mar-05-26 | Reiterated | Stifel Nicolaus | Buy | $56 → $85 |
| Mar-04-26 | Reiterated | HC Wainwright & Co. | Buy | $59 → $66 |
| Jan-07-26 | Reiterated | UBS | Neutral | $70 |
| Dec-18-25 | Reiterated | Guggenheim | Buy | $100 → $140 |
| Dec-17-25 | Reiterated | Barclays | Overweight | $70 → $55 |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 232 | 235 | 91 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | -38 | 2 | 164 | — | — | — | — | — | — | |
| Gross Profit | 270 | 232 | -73 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 63 | 51 | 42 | — | — | — | — | — | — | |
| Research and Development | 129 | 136 | 164 | — | — | — | — | — | — | |
| Other Operating Expense | 38 | -3 | -164 | — | — | — | — | — | — | |
| Operating Income | 41 | 48 | -115 | — | — | — | — | — | — | |
| Interest Expense | 84 | 80 | 50 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 19 | 20 | — | — | — | — | — | — | |
| Net Income Before Taxes | -27 | -13 | -145 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -27 | -13 | -145 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -27 | -13 | -145 | — | — | — | — | — | — | |
| Net Income | -27 | -13 | -145 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.85 | -0.46 | -5.12 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.85 | -0.46 | -5.12 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.08 | -0.46 | -5.12 | — | — | — | — | — | — | |
| EBITDA | 59 | 69 | -93 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.97 | 3.85 | 2.72 | — | — | — | — | — | — | |
| Gross Margin | 116.38 | 98.72 | -80.22 | — | — | — | — | — | — | |
| Operating Margin | 17.67 | 20.43 | -126.37 | — | — | — | — | — | — | |
| Net Margin | -11.64 | -5.53 | -159.34 | — | — | — | — | — | — | |
| Shares Outstanding | 29 | 28 | 28 | — | — | — | — | — | — | |
| Market Capitalization | 1,617 | 905 | 247 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schmid John P. | Director | Jun 15 '26 | Option Exercise | 0.00 | 6,030 | 0 | 37,652 | Jun 17 |
| RENTON HOLLINGS | Director | Jun 15 '26 | Option Exercise | 0.00 | 6,030 | 0 | 10,995 | Jun 17 |
| Orwin John A | Director | Jun 15 '26 | Option Exercise | 0.00 | 6,030 | 0 | 16,695 | Jun 17 |
| Schmid John P. | Director | Mar 30 '26 | Sale | 56.11 | 20,645 | 1,158,451 | 31,622 | Apr 01 |
| Faga Daniel | President, CEO | Mar 27 '26 | Sale | 61.61 | 17,679 | 1,089,199 | 495,965 | Mar 27 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Feb 11 '26 | Sale | 54.00 | 10,000 | 540,000 | 12,835 | Feb 13 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Feb 11 '26 | Option Exercise | 29.70 | 10,000 | 297,000 | 22,835 | Feb 13 |
| Marquet Magda | Director | Jan 15 '26 | Sale | 48.23 | 11,000 | 530,531 | 9,930 | Jan 16 |
| Marquet Magda | Director | Jan 15 '26 | Option Exercise | 26.11 | 11,000 | 287,210 | 20,930 | Jan 16 |
| Faga Daniel | President, CEO | Jan 08 '26 | Sale | 44.71 | 14,281 | 638,504 | 479,344 | Jan 09 |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | Jan 08 '26 | Sale | 44.71 | 2,515 | 112,446 | 21,852 | Jan 09 |
| Lizzul Paul F. | Chief Medical Officer | Jan 08 '26 | Sale | 44.71 | 3,650 | 163,192 | 42,088 | Jan 09 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Jan 08 '26 | Sale | 44.71 | 2,210 | 98,809 | 12,835 | Jan 09 |
| Faga Daniel | President, CEO | Jan 07 '26 | Option Exercise | 0.00 | 26,838 | 0 | 493,625 | Jan 09 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Jan 07 '26 | Option Exercise | 0.00 | 5,888 | 0 | 15,045 | Jan 09 |